Ultragenyx Pharmaceutical (RARE) Capital Leases (2019)

Ultragenyx Pharmaceutical (RARE) reported Capital Leases of $31.2 million for Q3 2019, down 5.34% quarter-over-quarter from $33.0 million in Q2 2019.

Ultragenyx Pharmaceutical (RARE) Capital Leases (2019) Analysis & Trends

Ultragenyx Pharmaceutical (RARE) has 1 years of Capital Leases data on file, last reported at $31.2 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Ultragenyx Pharmaceutical	2.77 Bn	2.36 Bn	106.00 Mn

Download Data